Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TBPH | Theravance Biopharma, Inc.

IndexRUT P/E- EPS (ttm)-1.05 Insider Own3.60% Shs Outstand56.68M Perf Week1.22%
Market Cap519.09M Forward P/E- EPS next Y-0.40 Insider Trans-0.86% Shs Float45.84M Perf Month-4.91%
Income-68.00M PEG- EPS next Q-0.21 Inst Own98.30% Short Float / Ratio19.63% / 19.72 Perf Quarter-15.02%
Sales51.30M P/S10.12 EPS this Y66.90% Inst Trans-0.34% Short Interest9.00M Perf Half Y-11.85%
Book/sh4.94 P/B1.84 EPS next Y51.90% ROA147.50% Target Price13.40 Perf Year-9.71%
Cash/sh2.94 P/C3.10 EPS next 5Y- ROE220.80% 52W Range8.76 - 12.03 Perf YTD-18.81%
Dividend- P/FCF- EPS past 5Y25.40% ROI-21.50% 52W High-24.27% Beta0.44
Dividend %- Quick Ratio7.80 Sales past 5Y27.30% Gross Margin- 52W Low4.05% ATR0.29
Employees111 Current Ratio7.80 Sales Q/Q23.40% Oper. Margin- RSI (14)40.70 Volatility2.32% 3.20%
OptionableYes Debt/Eq0.00 EPS Q/Q7.60% Profit Margin- Rel Volume0.81 Prev Close9.01
ShortableYes LT Debt/Eq0.00 EarningsAug 07 AMC Payout0.00% Avg Volume456.33K Price9.11
Recom2.00 SMA20-4.33% SMA50-5.78% SMA200-13.38% Volume367,605 Change1.11%
Date Action Analyst Rating Change Price Target Change
May-23-22Initiated SVB Leerink Outperform $12
Nov-05-21Upgrade JP Morgan Underweight → Neutral $12
Sep-15-21Downgrade JP Morgan Overweight → Underweight $7
Aug-25-21Downgrade Morgan Stanley Overweight → Underweight $27 → $14
Aug-24-21Downgrade Cowen Outperform → Market Perform $42 → $14
Oct-14-20Upgrade Morgan Stanley Equal-Weight → Overweight $32
Jul-07-20Initiated JP Morgan Overweight $29
Jun-15-20Initiated Morgan Stanley Equal-Weight $30
May-13-20Initiated Cowen Outperform $42
Jan-08-20Reiterated H.C. Wainwright Buy $25 → $30
Sep-06-23 11:30AM
Aug-31-23 05:55PM
Aug-29-23 06:00AM
Aug-28-23 06:05AM
Aug-09-23 06:25AM
09:54AM Loading…
Aug-08-23 09:54AM
Aug-07-23 05:25PM
Aug-01-23 10:00AM
Jul-24-23 06:00AM
Jul-03-23 09:00AM
Jun-08-23 11:14AM
Jun-07-23 11:30AM
May-18-23 01:50PM
03:41PM Loading…
May-11-23 03:41PM
May-10-23 11:34AM
May-09-23 06:00PM
May-08-23 05:55PM
May-04-23 10:00AM
May-01-23 10:01AM
Apr-24-23 06:00AM
Apr-19-23 02:42PM
Apr-17-23 07:47AM
Apr-14-23 04:23AM
Apr-11-23 04:05PM
06:00AM Loading…
Apr-10-23 06:00AM
Mar-31-23 12:41PM
Mar-30-23 05:22PM
Mar-29-23 11:30AM
Mar-10-23 06:56AM
Mar-08-23 02:50PM
Mar-02-23 06:00AM
Feb-28-23 02:17PM
Feb-27-23 06:15PM
Feb-23-23 07:46AM
Feb-21-23 06:00AM
Feb-16-23 10:01AM
Feb-15-23 10:00AM
Feb-09-23 06:00AM
Jan-09-23 06:00AM
Dec-25-22 09:39AM
Dec-07-22 11:30AM
Nov-22-22 04:15PM
Nov-18-22 06:00AM
Nov-11-22 08:20AM
Nov-08-22 08:34AM
Nov-07-22 05:45PM
Nov-02-22 04:30PM
Oct-31-22 06:00AM
Oct-27-22 10:02AM
Oct-26-22 10:02AM
Oct-25-22 06:00AM
Sep-28-22 06:00AM
Sep-20-22 09:36AM
Sep-19-22 02:28PM
Sep-08-22 11:30AM
Sep-06-22 06:00AM
Aug-14-22 08:06AM
Aug-05-22 11:53AM
Aug-04-22 07:25PM
Jul-28-22 06:00AM
Jul-27-22 10:01AM
Jul-26-22 10:01AM
Jul-18-22 10:20AM
Jul-14-22 06:04PM
Jul-13-22 05:29PM
Jul-11-22 05:07PM
Jun-06-22 08:38AM
May-13-22 01:57PM
May-06-22 04:15PM
May-05-22 07:15PM
May-04-22 06:30AM
May-02-22 06:30AM
Apr-26-22 03:01PM
Apr-13-22 06:30AM
Apr-12-22 06:30AM
Apr-11-22 06:30AM
Apr-06-22 06:00AM
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRAHAM RICHARD ASVP, RESEARCH & DEVELOPMENTSep 14Sale9.892,48224,547336,803Sep 18 06:08 PM
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSAug 22Sale9.471,80717,112340,566Aug 24 06:05 PM
GRAHAM RICHARD ASVP, RESEARCH & DEVELOPMENTAug 11Sale9.992,32223,197349,746Aug 15 06:09 PM
GRAHAM RICHARD ASVP, RESEARCH & DEVELOPMENTJul 14Sale9.842,32222,848352,068Jul 18 06:14 PM
GRAHAM RICHARD ASVP, RESEARCH & DEVELOPMENTJun 14Sale10.692,32224,822354,390Jun 16 06:14 PM
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSJun 08Sale11.131,79019,923352,833Jun 12 06:08 PM
GRAHAM RICHARD ASVP, RESEARCH & DEVELOPMENTMay 15Sale11.262,32226,146367,172May 17 06:17 PM
GRAHAM RICHARD ASVP, RESEARCH & DEVELOPMENTApr 14Sale11.882,32327,597369,494Apr 18 05:49 PM
GRAHAM RICHARD ASVP, RESEARCH & DEVELOPMENTMar 14Sale10.322,32323,973371,817Mar 16 07:04 PM
Farnum RhondaSVP, COMM & MEDICAL AFFAIRSMar 09Sale10.204,00040,800360,190Mar 13 05:57 PM
GRAHAM RICHARD ASVP, RESEARCH & DEVELOPMENTMar 06Sale10.052,32323,346374,140Mar 08 07:34 PM
Winningham Rick ECHIEF EXECUTIVE OFFICERDec 14Sale11.1950,000559,5001,350,797Dec 16 07:36 PM
GRAHAM RICHARD ASVP, RESEARCH & DEVELOPMENTDec 01Sale10.732,08422,361313,520Dec 05 05:59 PM
Hindman Andrew A.SVP, CHIEF FINANCIAL OFFICERNov 18Sale11.0265,000716,242409,771Nov 22 04:07 PM